A growing pipeline of T-SIGn® therapeutics aiming to enable a patient’s immune system to recognize, attack, and clear solid tumors.
Akamis Bio has a growing pipeline of T-SIGn® therapeutics capable of driving the intratumoral expression of a broad range of therapeutic proteins, as well as immunologically active biomolecules which aim to enable a patient’s immune system to recognize, attack, and clear solid tumors.
With more than 200 patients treated across our clinical studies, T-SIGn® therapeutics have demonstrated a consistent safety & tolerability profile, as well as promising preliminary evidence of clinical activity.
producing a secreted CD40 agonist monoclonal antibody
producing IL-12, IL-15 and a chemokine
Product Concept: Tumor-specific delivery of potent immune cell recruitment & activating agents avoiding systemic toxicity
Product Concept: Tumor-specific delivery of CAR-T targets to enhance the efficacy and/or improve the safety profile of the cell therapy
Transgene payload packages including natural and synthetic tumor antigens
CAR T-cell targeting & activation